Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States-Reference-Cited by-同舟云学术

Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

Published:2020-10-06 Issue:4 Volume:98 Page:1219-1256
ISSN:0887-378X
Container-title:The Milbank Quarterly
language:en
Short-container-title:The Milbank Quarterly

Author:

SALCHER‐KONRAD MAXIMILIAN¹,NACI HUSEYIN¹,DAVIS COURTNEY²

Affiliation:

1. London School of Economics and Political Science

2. King's College London

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1468-0009.12476

Reference59 articles.

1. From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

2. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency

3. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements

4. Accelerated Access to Innovative Medicines for Patients in Need

5. European Medicines Agency.PRIME: A Two‐Year Overview.London England:European Medicines Agency;2018.https://www.ema.europa.eu/en/documents/report/prime-two-year-overview_en.pdf. Accessed October 8 2019.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health technology assessments of new specialized therapies: A typology of key challenges and potential policy solutions;Health Policy and Technology;2024-09

2. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04

3. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06

4. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures;Cancers;2024-04-12

5. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe;The Lancet Regional Health - Europe;2024-03